University of Medicine and Pharmacy Carol Davila, Internal Medicine Chair, Bucharest, Romania.
Clinical Immunology Laboratory CDPC, Colentina Clinical Hospital, Bucharest, Romania.
Rom J Intern Med. 2021 May 8;59(2):101-111. doi: 10.2478/rjim-2020-0037. Print 2021 Jun 1.
Systemic sclerosis (Ssc) is an autoimmune disease characterized by graduate cutaneous and tissue fibrosis development and irreversible fibroproliferative vascular changes.The aim of the current systematic review was to update the list of proteomic candidate biomarkers identified from Ssc samples with mass spectrometry techniques. Medline and Scopus databases were searched on 1 September 2020. Relevant articles were searched from March 2014 until September 2020. Two independent reviewers evaluated the retrieved articles. From a total of 97 articles, 9 articles were included in the final analysis summarizing 539 candidate proteomic biomarkers from various samples from Ssc patients (a larger number compared to the previous systematic review). Most biomarkers were identified from cutaneous biopsies. Only 5 articles included a validation step of the findings with only 13 biomarkers being validated. Although many candidate biomarkers were additionally identified, independent validation studies are needed in order to evaluate the importance of these biomarkers for Ssc patients.
系统性硬皮病（Ssc）是一种自身免疫性疾病，其特征为渐进性皮肤和组织纤维化发展以及不可逆转的纤维增生性血管变化。本系统综述的目的是更新通过质谱技术从 Ssc 样本中鉴定出的蛋白质组候选生物标志物列表。于 2020 年 9 月 1 日检索 Medline 和 Scopus 数据库。从 2014 年 3 月至 2020 年 9 月检索相关文章。两名独立的审查员评估了检索到的文章。从总共 97 篇文章中，有 9 篇文章被纳入最终分析，总结了 539 种来自 Ssc 患者各种样本的蛋白质组候选生物标志物（与之前的系统综述相比数量更多）。大多数生物标志物是从皮肤活检中鉴定出来的。只有 5 篇文章包含对这些发现的验证步骤，只有 13 个生物标志物得到验证。尽管还另外鉴定了许多候选生物标志物，但需要进行独立的验证研究，以评估这些生物标志物对 Ssc 患者的重要性。
